Loading ...
Sorry, an error occurred while loading the content.
 

Pegintron (Peginterferon Alfa-2b) Should To Be Given Twice Weekly

Expand Messages
  • claudine intexas
    DGNews Hepatitis C Virus Drug Pegintron (Peginterferon Alfa-2b) Should To Be Given Twice Weekly VIENNA, AUSTRIA -- July 29, 2003 -- A study published in the
    Message 1 of 1 , Aug 6, 2003
      DGNews

      Hepatitis C Virus Drug Pegintron (Peginterferon Alfa-2b) Should To Be
      Given Twice Weekly

      VIENNA, AUSTRIA -- July 29, 2003 -- A study published in the July
      issue of the Journal of Viral Hepatitis(1) shows that the currently
      prescribed once weekly dosing schedule of peginterferon alfa-2b
      (PegIntron�-Schering-Plough) does not provide sustained suppression
      of the hepatitis C virus (HCV). The study found that to achieve
      continuous drug exposure and to improve viral clearance,
      peginterferon alfa-2b has to be given at least twice weekly.

      The study, conducted at the University of Vienna, investigated
      whether twice weekly dosing of PegIntron� improves viral kinetics
      over once weekly dosing. Twenty interferon-na�ve patients with
      chronic hepatitis C genotype 1 were randomised to receive either
      1.0mcg/kg peginterferon alfa-2b once weekly (Group A, 10 patients) or
      twice weekly (Group B, 10 patients) for four weeks. Serum
      concentrations and viral load were measured. In Europe, the
      monotherapy dose for peginterferon alfa-2b is 0.5 or 1.0 mcg/kg/week,
      of which the 1.0 dose was used for this monotherapy study.

      Key study findings:
      � Serum concentrations of peginterferon alfa-2b reached maximum
      levels 24 hours after injection followed by a linear decline over the
      subsequent days. On the day before administration of the next dose,
      no drug was detectable in 90 per cent of patients in Group A (once
      weekly dosing). This same pattern was observed during the next three
      weeks of therapy.
      � In contrast, in Group B with twice-weekly dosing, drug levels were
      detectable at any given time point and higher than in Group A.
      � Viral load decreased in all patients within 2 days after the first
      dose of peginterferon alfa-2b but increased again on day 3. In Group
      A with once weekly dosing, viral load continued to increase
      throughout the week, and a similar pattern was observed in the second
      week. In contrast, in Group B with twice weekly dosing, viral load
      decreased again on day 4 and remained lower throughout the four-week
      study period.

      � The authors noted that the viral load increases in parallel with
      the decrease of peginterferon alfa-2b, and this "clearly indicates
      that this rebound of HCV RNA is because of insufficient interferon
      levels in the body. This rebound may be predictive for nonresponse to
      peginterferon alfa-2b/ribavirin therapyi.(1)"

      Previous studies have also shown that the once weekly administration
      of PegIntron� does not result in the continuous decline in viral load

      References:
      1. Formann, E et al. Twice-weekly administration of peginterferon
      alfa-2b improves viral kinetics in patients with chronic hepatitis C
      genotype 1. J. Viral Hepatitis. 2003;10: 271-276.

      SOURCE: Burson-Marsteller


      __________________________________
      Do you Yahoo!?
      Yahoo! SiteBuilder - Free, easy-to-use web site design software
      http://sitebuilder.yahoo.com
    Your message has been successfully submitted and would be delivered to recipients shortly.